

BTC Health (BTC) - ASX Announcement

10 February 2025

BTC expands distribution partnership with Arna Pharma

- License and distribution agreement for Bronchitol and Aridol converted from an initial 10year term to an indefinite license
- BTC to earn royalties from sales of Bronchitol and Aridol in Singapore and Malaysia
- BTC granted first right of refusal to Arna Pharma's new product pipeline

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce that its whollyowned investee company, BTC Pharma, has amended its existing License and Distribution Agreement for the Bronchitol and Aridol products (Products) and extended its partnership with Arna Pharma, with effect from 1 February 2025.

Under the terms of the amendment, BTC Pharma has assigned Singapore and Malaysia distribution rights to the Products to Arna Pharma. Arna Pharma will pay BTC Pharma a single-digit royalty on sales in these markets for the first 3 years and has granted BTC Pharma an indefinite license to the Products for the Australian and New Zealand markets.

Arna Pharma is building a pipeline of novel pharmaceutical products. It has granted BTC Pharma the first right of refusal to commercialise its specialty products in the Australian and New Zealand markets.

Commenting on the partnership, BTC Health Executive Chairman Dr Richard Treagus said, "This expanded partnership agreement with Arna Pharma combines the established strengths of Arna Pharma's product development and manufacturing capabilities and BTC Pharma's distribution and marketing expertise. We are very excited by the potential of bringing novel pharmaceutical products to Australian patients."

Arna Pharma Managing Director, Mr Hemant Gulhane said, "We are delighted to strengthen our partnership with BTC Pharma, extending our collaboration to new markets. This agreement reflects our shared commitment to delivering innovative respiratory solutions to patients in Singapore and Malaysia. With an indefinite license for Bronchitol and Aridol, we are positioned for long-term success. Additionally, BTC Pharma's first right of refusal for our new product pipeline underscores the trust in Arna Pharma's innovation. We look forward to expanding access to high-quality treatments and achieving new milestones together."

Authorisation

This announcement was authorised for release to the ASX by the board of directors of BTC Health Limited, Level 1, 10 Oxley Rd, Hawthorn, VIC 3122.

Contact Information

Richard Treagus Chairman **BTC Health Limited** Ph: +61 417 520 509

E-mail: rtreagus@btchealth.com.au

Tracy Weimar Company Secretary **BTC Health Limited** Ph: +61 03 9692 7222

E-mail: tracy.weimar@vistra.com

About BTC Health

BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:

- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.

About Arna Pharma

Arna Pharma is an international contract pharmaceutical Development and Manufacturing Organization dedicated to improving lives through innovative pharmaceutical solutions. Its mission is to develop and deliver breakthrough pharmaceutical solutions that enhance the well-being of individuals and communities worldwide. With a team of experienced professionals and state-of-the-art facilities, Arna Pharma is committed to delivering excellence in every aspect.